Home
Search
Search Results
Previously Searched
3113 results found
Expand All
Apply All
3113 results found

Climate Policy Innovation Series: Fueling the Energy Transition
Webinars  •  November 2, 2023
View this conversation highlighting how BIO member companies are leveraging biotechnology innovations to enable advances in climate adaptation, mitigation, and resilience. Hear how diverse feedstocks and manufacturing processes are targeting emission reduction breakthroughs in hard-to-reach sectors. Learn how regulation and policy can better incentivize innovation and be structured to support new and emerging technologies throughout research, development, demonstration, and deployment.
Read More
bio_climate-policy-innovation-series_fueling-the-energy-transition

First human CRISPR drug moves forward
Good Day BIO Newsletter  •  November 1, 2023
Today, we look at what happened during yesterday’s FDA advisory panel review of exa-cel, and a recently reintroduced bill that would support tax incentives for biofuels with more accurate measures of carbon reduction. (452 words, 2 minutes, 15 seconds)
Read More

Senators, BIO oppose proposed Medicaid rule
Good Day BIO Newsletter  •  October 31, 2023
Happy Halloween. A scary proposed rule on Medicaid drug coverage would harm patient access. Plus, today’s new episode of the I am BIO Podcast explores the possibilities of synbio. (568 words, 2 minutes, 50 seconds)
Read More

The Synbio Revolution is Here
I am BIO Podcast  •  October 31, 2023
Innovative companies are using synthetic biology to engineer organisms and create new materials that could transform every sector of our economy, from health care to food and energy production. Those companies say we’ve entered a synbio revolution, and it holds potential to improve the health of people and our planet. In this episode, we talk with three synbio experts about how this convergence of genetic engineering, computer science and other scientific disciplines is making our world more sustainable.
Read More
Synbio

BIO Federal Government Relations Committee Meeting
October 30, 2023
The Federal Government Relations Committee concentrates on educating and lobbying government officials regarding legislative proposals affecting the biotechnology industry. The committee reviews the BIO legislative and regulatory agenda as a whole to set priorities and strategies; initiates BIO policy discussions regarding legislation; and provides advice and recommendations to the Board. Committee members meet with various government officials and their staffs to gain information, offer insight and advice, and buttress BIO positions. The committee collaborates on substance and formulates legislative strategy for major BIO priorities. For more information and to join the Committee, please contact Amanda Galich (agalich@bio.org).
Read More

Comments to FDA on the Agency’s Information Technology Strategy
Letters, Testimony & Comments  •  October 30, 2023
BIO and PhRMA submitted joint comments on the U.S. Food and Drug Administration’s Information Technology Strategy (Docket No. FDA-2023-N-3636)
Read More

Bee Vaccine Generates Buzz
Good Day BIO Newsletter  •  October 30, 2023
BIO member Dalan Animal Health’s honeybee vaccine is generating buzz—here’s why. Plus, a D.C.-area man has been named “Miracle Man” after surviving sepsis, but he now needs a kidney. We tell you his story and why developing new antimicrobials matters. (423 words, 2 minutes, 6 seconds)
Read More

BIO Comments to FDA on Manufacturing Changes and Comparability for Human Cellular and Gene Therapy Products
Letters, Testimony & Comments  •  October 27, 2023
BIO submits comments and specific recommendations to the U.S. Food and Drug Administration on their Draft Guidance for Industry (Docket No. FDA-2023-D-2436)
Read More

BIO hits the Hill, Senators intro ORPHAN Cures Act
Good Day BIO Newsletter  •  October 27, 2023
A busy week on Capitol Hill concluded with visits by BIO members and the introduction of the Senate’s version of the ORPHAN Cures Act. (435 words, 2 minutes, 10 seconds)
Read More

BIO Chair: PBMs and IRA harm generics
Good Day BIO Newsletter  •  October 26, 2023
It’s all about BIO thought leadership today—explaining the impact of PBMs and price controls on generics, and why we need to pass the Farm Bill to advance needed biotech solutions. (482 words, 2 minutes, 24 seconds)
Read More